Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Pertuzumab
DATE: 01/06/2026
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
